Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice.
Approximately 50-70% of the risk for developing nicotine dependence is attributed to genetics; therefore, it is of great significance to characterize the genetic mechanisms involved in nicotine reinforcement and dependence in hopes of generating better smoking cessation therapies. The overall goal of these studies was to characterize behavioral and pharmacological responses to nicotine in C57Bl/6 (B6) and DBA/2 (D2) mice, two inbred strains commonly used for genetic studies on behavioral traits. B6 and D2 mice where subjected to a battery of behavioral tests to measure nicotine's acute effects, calcium-mediated antinociceptive responses, tolerance to chronic treatment with osmotic mini pumps, and following three days of nicotine withdrawal. In general, D2 mice were less sensitive than B6 mice to the acute effects of nicotine, but were more sensitive to blockade of nicotine-induced antinociceptive responses by a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. B6, but not D2 mice, developed tolerance to nicotine and nicotine conditioned place preference (CPP). While B6 and D2 mice both expressed some physical withdrawal signs, affective withdrawal signs were not evident in D2 mice. These results provide a thorough, simultaneous evaluation of the pharmacological and behavioral differences to experimenter-administered nicotine as measured in several behavioral tests of aspects that contribute to smoking behavior. The B6 and D2 strains show wide phenotypic differences in their responses to acute or chronic nicotine. These results suggest that these strains may be useful progenitors for future genetic studies on nicotine behaviors across batteries of mouse lines such as the BXD recombinant inbred panel.
Jackson
Kia J
KJ
Department of Pharmacology and Toxicology, Medical Campus, Virginia Commonwealth University, Richmond, VA 23298-0613, USA. jacksonkj@vcu.edu
Walters
Carrie L
CL
Miles
Michael F
MF
Martin
Billy R
BR
Damaj
M Imad
MI
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000037:antagonists & inhibitors; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D004361:Drug Tolerance / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009483:Neuropsychological Tests; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy; D010641:Phenotype; D013028:Space Perception / Q000187:drug effects / Q000502:physiology; D013045:Species Specificity; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D004791:Enzyme Inhibitors; D018722:Nicotinic Agonists; D009538:Nicotine; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2